Posted by Michael Wonder on 12 Apr 2021
ICER to use Aetion observational RWE to update value assessment of treatments for hereditary angioedema
12 April 2021 - New ICER pilot will incorporate more than 24 months of observational real world demographic, utilisation, and cost data to further clarify therapies’ value.
The Institute for Clinical and Economic Review today announced it is using observational real world evidence to update its 2018 assessment of three therapies for long-term prophylaxis against hereditary angioedema attacks: lanadelumab (Takhzyro, Takeda), and two C1 esterase inhibitors (Haegarda, CSL Behring; and Cinryze, Takeda).
